Muscular Synergies and Behavioral Adaptations of Gait in Pain Anticipation (SYAMAPP)
Launched by UNIVERSITE DE PICARDIE JULES VERNE · Apr 14, 2025
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The SYAMAPP trial is a study designed to explore how thinking about pain might affect how we walk and respond physically. In this study, healthy participants will apply a cream that is described differently to two groups: one group will be told it might cause pain, while the other group will be told it is harmless. Researchers will then observe how each group walks and responds to different tasks to see if the anticipation of pain changes their movements or feelings.
To be eligible for this study, participants should be between 18 and 35 years old and in good health, meaning they shouldn't have any diagnosed conditions that affect the nervous system, muscles, or heart. They should also be able to walk without assistance for at least 10 minutes and have a body mass index (BMI) of less than 30. Participants will be asked to avoid certain things like painkillers, cigarettes, and caffeine before the study. This trial is not yet recruiting participants, so there will be more information available once it starts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18-35 years
- • Healthy participant with no self-reported diagnosed neurological, musculoskeletal, or cardiovascular disorders
- • Body Mass Index (BMI) \< 30
- • Ability to walk unaided for at least 10 minutes without major physical limitations
- Exclusion Criteria:
- • Presence of pain at the time of testing
- • Self-reported diagnosed condition affecting mobility
- • Known allergy to any component of the study cream
- • Allergy to EMG electrode adhesives
- • Inability to stand unassisted for more than 1 minute
- • Inability to walk/run at the required speed and distance
- • Weight exceeding 150 kg (due to treadmill limitations)
- * Recent intake of:
- • Analgesics (within 6 hours)
- • Cigarettes (within 6 hours)
- • Caffeine (within 2 hours)
- • Skin lesions at the cream application site
- • Pregnancy
- • Failure to understand instructions
- • Daytime pain reported by participant on day of experimentation
About Universite De Picardie Jules Verne
The Université de Picardie Jules Verne is a prominent academic institution located in Amiens, France, dedicated to advancing medical research and education. With a strong emphasis on interdisciplinary collaboration, the university fosters innovative clinical trials aimed at improving health outcomes and enhancing patient care. Its commitment to excellence in research is supported by state-of-the-art facilities and a network of expert researchers and practitioners. The institution actively engages in partnerships with healthcare organizations and industry stakeholders to drive translational research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Trial Officials
Thierry Lelard, PhD
Study Director
Lecturer
Maryne Cozette, PhD
Study Director
Lecturer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported